# RESEARCH
## Prof halts MS trial after fears New treatment now awaits FDA approval 
### JULIA BROWNELL SENIOR STAFF WRITER 
A cutting-edge vascular treatment
program for multiple sclerosis (MS) at
Stanford Medical School was terminat
ed in December after some patients
undergoing the therapy had complica
tions.
Michael Dake, a Stanford professor
of cardiovascular surgery, had surgically
widened the internal jugular veins of
select MS patients with stents, or mesh
wire tubes. The procedure, called an
angioplasty, attempted to fix a blockage
limiting blood flow from the brain to
the heart.
This insufficiency, termed CCSVT,
was originally discovered by Dr. Paolo
